Furtherly, HAT1 silencing increased three pancreatic cancer cell lines sensitivity to gemcitabine; HAT1 overexpression had the opposite effect (Fig. 1b and Fig. S1a, b). This evidence concerns the gene HAT1 and familial pancreatic carcinoma.